محمد أحمد السيد قاسم
أستاذ
Synthesis, structural characterization and DNA binding affinity of new bioactive nano‐sized transition metal complexes with sulfathiazole azo dye for therapeutic applications
Appl Organometal Chem • 2019
معلومات البحث
المؤلفون
Fawaz A. Saad; Hoda A. El‐Ghamry; Mohammed A. Kassem
الكلمات المفتاحية
anticancer, characterization, DNA binding, nano‐sized complexes, sulfthiazole
المجلة العلمية
Appl Organometal Chem
الناشر
Wiley
المجلد
https://doi.org/10.1002/aoc.4965
العدد
Not Available
الصفحات
Not Available
publication.type
International
رابط البحث
Not Available
المواد المرفقة
Not Available
الملخص
The azo dye ligand 4‐(5‐chloro‐2‐hydroxyphenylazo)‐N‐thiazol‐2‐
ylbenzenesulfonamide (H2L) formed by the coupling reaction of sulfathiazole
and p‐chlorophenol was synthesized and characterized using elemental
analysis and Fourier transform infrared (FT‐IR) as well as UV–visible spectra.
Nano‐sized divalent Cu, Co, Ni, Mn and Zn complexes of the synthesized azo
dye ligand were prepared and investigated using various spectroscopic and
analytical techniques. Elemental and thermal analyses indicated the formation
of the Cu(II), Ni(II) and Mn(II) complexes in a molar ratio of 1:2 (L:M) while
Co(II) and Zn(II) complexes exhibited a 1:1 (M:L) ratio. FT‐IR spectral studies
confirmed the coordination of the ligand to the metal ions through the phenolic hydroxyl oxygen, azo nitrogen, sulfonamide oxygen and/or thiazole
nitrogen. The geometric arrangements around the central metal ions were
investigated applying UV–visible and electron spin resonance spectra, thermogravimetric analysis and molar conductance measurements. X‐ray diffraction
patterns revealed crystalline nature of H2L and amorphous nature of all synthesized complexes. Transmission electron microscopy images confirmed
nano‐sized particles and their homogeneous distribution over the complex
surface. Antibacterial, antifungal and antitumour activities of the investigated
complexes were screened compared with familiar standard drugs to confirm
their potential therapeutic applications. The Cu(II) complex showed IC50 of
3.47 μg ml−1 (5.53 μM) against hepatocellular carcinoma cells, which means
that it is a more potent anticancer drug compared with the standard cisplatin
(IC50 = 3.67 μg ml−1 (12.23 μM)). Furthermore, the Co(II), Ni(II), Cu(II) and
Zn(II) complexes displayed IC50 greater than that of an applied standard
anticancer agent (5‐flurouracil) towards breast carcinoma cells. Hence, these
complexes can be considered as promising anticancer drugs. The mode of
binding of the complexes with salmon serum DNA was determined through
electronic absorption titration and viscosity studies.
ylbenzenesulfonamide (H2L) formed by the coupling reaction of sulfathiazole
and p‐chlorophenol was synthesized and characterized using elemental
analysis and Fourier transform infrared (FT‐IR) as well as UV–visible spectra.
Nano‐sized divalent Cu, Co, Ni, Mn and Zn complexes of the synthesized azo
dye ligand were prepared and investigated using various spectroscopic and
analytical techniques. Elemental and thermal analyses indicated the formation
of the Cu(II), Ni(II) and Mn(II) complexes in a molar ratio of 1:2 (L:M) while
Co(II) and Zn(II) complexes exhibited a 1:1 (M:L) ratio. FT‐IR spectral studies
confirmed the coordination of the ligand to the metal ions through the phenolic hydroxyl oxygen, azo nitrogen, sulfonamide oxygen and/or thiazole
nitrogen. The geometric arrangements around the central metal ions were
investigated applying UV–visible and electron spin resonance spectra, thermogravimetric analysis and molar conductance measurements. X‐ray diffraction
patterns revealed crystalline nature of H2L and amorphous nature of all synthesized complexes. Transmission electron microscopy images confirmed
nano‐sized particles and their homogeneous distribution over the complex
surface. Antibacterial, antifungal and antitumour activities of the investigated
complexes were screened compared with familiar standard drugs to confirm
their potential therapeutic applications. The Cu(II) complex showed IC50 of
3.47 μg ml−1 (5.53 μM) against hepatocellular carcinoma cells, which means
that it is a more potent anticancer drug compared with the standard cisplatin
(IC50 = 3.67 μg ml−1 (12.23 μM)). Furthermore, the Co(II), Ni(II), Cu(II) and
Zn(II) complexes displayed IC50 greater than that of an applied standard
anticancer agent (5‐flurouracil) towards breast carcinoma cells. Hence, these
complexes can be considered as promising anticancer drugs. The mode of
binding of the complexes with salmon serum DNA was determined through
electronic absorption titration and viscosity studies.
